Osaka, Japan

Yasuo Hirooka

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2018-2023

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Yasuo Hirooka: Innovator in Pharmaceutical Chemistry

Introduction

Yasuo Hirooka is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic potential. With a total of 5 patents to his name, Hirooka's work is recognized for its impact on medical science.

Latest Patents

One of Hirooka's latest patents involves a Dihydroindolizinone derivative, which is a compound represented by a specific general formula. This compound acts as a potent FXIa inhibitor and exhibits excellent oral absorption properties and kinetics in the bloodstream. It is capable of exerting a strong anti-coagulation activity over an extended period after oral administration. Notably, there is a discrepancy between its anti-coagulation activity and its CYP-inhibiting activity. This unique profile allows the compound, or its salt, solvate, N-oxide form, or prodrug, to be utilized as an effective prophylactic and/or therapeutic agent for vascular occlusive diseases.

Career Highlights

Hirooka is currently associated with Ono Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work has been instrumental in creating innovative solutions for complex medical challenges.

Collaborations

Hirooka collaborates with esteemed colleagues, including Motoyuki Tanaka and Takashi Kondo, to further enhance the scope and impact of his research.

Conclusion

Yasuo Hirooka's contributions to pharmaceutical chemistry exemplify the spirit of innovation in the medical field. His work on Dihydroindolizinone derivatives showcases the potential for new therapeutic agents that can significantly improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…